—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Guardant Health Inc (GH) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GH, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.63 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How GH has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.63 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Guardant Health Inc moved 0.63% on average · correlation 0.10 · higher than 65% of US names
  • Beta, last 3 months 0.08 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.62% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.08% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GH on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Guardant Health Inc

GH in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Guardant Health develops blood and tissue tests that detect and monitor cancer, using DNA fragments shed by tumours into the bloodstream. Its main products profile tumour mutations for treatment choices, track cancer recurrence after treatment, and screen adults for colorectal cancer through a blood draw rather than a colonoscopy. It also sells software and data services that connect test results to clinical trials for biopharmaceutical customers. The company is based in Palo Alto and serves oncologists, hospitals and drug developers in the United States and abroad.
Where it sits in the stack
Guardant Health sits in our Healthcare sector, within Diagnostics & Research, rather than in a Closelooknet index sleeve; it carries no seat in our build-out indices.
Who it is priced against
The diary groups it with scored Healthcare names based in the United States, including Regeneron, Vertex, BeiGene and Veeva; Exact Sciences is the wider competitor the market names in liquid-biopsy diagnostics.
Why Closelooknet tracks it
It carries a Closelooknet score, with momentum the strongest of its modules and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in an edition.
What the diary watches
Whether the colorectal screening test gains wider reimbursement and test volume, since that would shift the balance between its momentum and its valuation reading.

Guardant Health Inc (GH) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Guggenheim, 2026-10-01

The Street on this name

Analyst actions and the latest print for GH from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Guggenheim — target 200 from 190 Target raised to $200 from $190 (+12.8% to spot) 2026-10-01

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Guardant Health Inc (GH)?

Guardant Health Inc trades as GH on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is GH in a Closelooknet index?

Not currently — Guardant Health Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does GH trade against its moving averages?

Uptrend stack intact: Trades +2.4% vs the 50-day and +36.8% vs the 200-day average, 10.6% below the 52-week high and +179.8% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Guardant Health Inc compare with its peers?

Against its peer group (Diagnostics & Research · US), Guardant Health Inc (GH) sits 10.6% below its 52-week high, 2.4% above its 50-day average; Medpace Holdings Inc (MEDP) is 11.1% below, Natera Inc (NTRA) is 0.4% below, Illumina Inc (ILMN) is 0.9% below. Put any of them next to GH in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Guardant Health Inc trade when bond yields rise?

Over the past year Guardant Health Inc had a beta of 0.63 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 65% of US names. On the 10 sessions in which long bonds fell most it moved −1.62% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Guardant Health Inc do?

Guardant Health develops blood and tissue tests that detect and monitor cancer, using DNA fragments shed by tumours into the bloodstream. Its main products profile tumour mutations for treatment choices, track cancer recurrence after treatment, and screen adults for colorectal cancer through a blood draw rather than a colonoscopy. It also sells software and data services that connect test results to clinical trials for biopharmaceutical customers. The diary groups it with scored Healthcare names based in the United States, including Regeneron, Vertex, BeiGene and Veeva; Exact Sciences is the wider competitor the market names in liquid-biopsy diagnostics.

Where does Guardant Health Inc sit in the AI build-out?

Guardant Health sits in our Healthcare sector, within Diagnostics & Research, rather than in a Closelooknet index sleeve; it carries no seat in our build-out indices. It carries a Closelooknet score, with momentum the strongest of its modules and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in an edition.

What has Wall Street done on Guardant Health Inc recently?

The most recent analyst action on Guardant Health Inc on the Closelooknet wire is a price target by Guggenheim on 2026-10-01 (target 200 from 190). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for GH, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.